First PARP Inhibitor Approved for Breast Cancer [News in Brief]

Olaparib also becomes the first targeted therapy for patients with germline BRCA mutations.

from Cancer via ola Kala on Inoreader http://ift.tt/2rQfcqJ
via IFTTT